Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.65 Insider Own10.33% Shs Outstand12.82M Perf Week12.43%
Market Cap552.82M Forward P/E- EPS next Y-4.10 Insider Trans0.00% Shs Float11.64M Perf Month26.79%
Income-39.03M PEG- EPS next Q-1.05 Inst Own83.69% Short Float8.40% Perf Quarter13.48%
Sales0.00M P/S- EPS this Y-241.98% Inst Trans-32.38% Short Ratio7.90 Perf Half Y218.79%
Book/sh13.28 P/B3.21 EPS next Y1.52% ROA-26.57% Short Interest0.98M Perf Year183.93%
Cash/sh13.06 P/C3.26 EPS next 5Y25.10% ROE-30.96% 52W Range12.20 - 53.00 Perf YTD119.76%
Dividend Est.- P/FCF- EPS past 5Y-16.09% ROI-21.39% 52W High-19.64% Beta1.47
Dividend TTM- Quick Ratio14.74 Sales past 5Y-20.00% Gross Margin- 52W Low249.10% ATR (14)2.55
Dividend Ex-Date- Current Ratio14.74 EPS Y/Y TTM-143.04% Oper. Margin0.00% RSI (14)72.30 Volatility7.37% 7.09%
Employees91 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.17 Target Price51.00
Option/ShortNo / Yes LT Debt/Eq0.07 EPS Q/Q-290.56% Payout- Rel Volume0.69 Prev Close41.99
Sales Surprise- EPS Surprise3.29% Sales Q/Q- EarningsMay 10 BMO Avg Volume123.73K Price42.59
SMA2020.41% SMA5021.99% SMA20064.78% Trades Volume85,842 Change1.43%
Date Action Analyst Rating Change Price Target Change
Jun-11-24Initiated Robert W. Baird Outperform $54
Apr-29-24Initiated Leerink Partners Outperform $46
Mar-21-24Initiated William Blair Outperform $61
Jan-08-24Initiated H.C. Wainwright Buy $45
Jan-05-24Initiated Stifel Buy $31
Jan-04-24Initiated TD Cowen Outperform
Jun-05-24 07:30AM
Jun-03-24 07:30AM
May-10-24 01:54PM
May-07-24 06:19AM
04:36PM Loading…
Apr-22-24 04:36PM
Mar-20-24 05:31AM
Mar-18-24 04:14PM
Mar-04-24 07:30AM
Feb-29-24 07:30AM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Dec-19-23 07:00AM
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.